Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Withdrawal in Patients With Coronary Artery Disease.

Journal of the American College of Cardiology·2026
Same author

Derivation and external validation of a deep learning model to predict changes in coronary plaque burden.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same author

Aspirin after PCI in Acute Coronary Syndromes. Reply.

The New England journal of medicine·2026
Same author

Aspirin may take a back row seat for non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention.

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Dapagliflozin in Acute Cardiovascular Conditions: Insights From the DEFENDER Trial.

JACC. Advances·2025
Same author

Prasugrel or ticagrelor monotherapy vs dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndromes: a landmark analysis from the NEOMINDSET trial.

European heart journal·2025

Related Experiment Video

Updated: May 12, 2026

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention
11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

The Supralimus sirolimus-eluting stent.

Pedro A Lemos1, Igor Bienert

  • 1Department of Interventional Cardiology, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.

Expert Review of Medical Devices
|April 20, 2013
PubMed
Summary

The Supralimus sirolimus-eluting stent, featuring a biodegradable polymer coating, effectively reduces repeat interventions for coronary artery disease. It shows promising safety by potentially decreasing late-term stent thrombosis risk.

Area of Science:

  • Bioengineering
  • Cardiovascular Research
  • Polymer Science

Background:

  • Biodegradable polymeric coatings are crucial for enhancing the vascular compatibility of coronary drug-eluting stents (DESs).
  • The Supralimus stent utilizes a novel biodegradable polymer blend for sirolimus delivery.
  • This stent represents an advancement in metallic stent technology for routine cardiovascular interventions.

Purpose of the Study:

  • To review the features and scientific data of the Supralimus sirolimus-eluting stent.
  • To evaluate the efficacy and safety of this biodegradable polymer-based DES.
  • To compare its performance against other DESs and bare metal stents.

Main Methods:

  • Review of clinical data from the SERIES-I and PAINT trials.

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Related Experiment Videos

Last Updated: May 12, 2026

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention
11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

  • Analysis of stent platform, biodegradable polymer composition (poly-l-lactide, poly-dl-lactide-co-glycolide, polyvinyl pyrrolidone), and coating thickness (4-5 µm).
  • Assessment of sirolimus elution kinetics (48 days) and dosage (1.4 µg/mm²).

    • Main Results:

    • The SERIES-I study reported low binary restenosis rates (0% in-stent, 1.7% in-segment) and minimal late lumen loss (0.09 ± 0.28 mm).
    • The PAINT trial demonstrated that pooled DES groups had similar cardiac death/myocardial infarction rates but significantly lower repeat interventions (10% vs. 29.9%) compared to bare stents.
    • Definite or probable stent thrombosis incidence was 2.3% over 3 years, with a notable decrease in later years.

    Conclusions:

    • The Supralimus stent is effective in reducing the need for reintervention in coronary artery disease patients.
    • The stent may offer an improved safety profile by potentially lowering the risk of late-term stent thrombosis.
    • Further research is warranted to definitively confirm the long-term safety and efficacy findings.